DeepMed Research

AIO-Studien-gGmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 2007-01-01

Employees: 11

Market Cap: -

Website: http://www.aio-studien-ggmbh.de

Clinical Trials

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

Phase 2

Terminated

Conditions: Activating EGFR Mutation
Non-squamous Non-small Cell Lung Cancer Stage IIIA
Non-squamous Non-small Cell Lung Cancer Stage IIIB
NSCLC
Non-squamous Non-small Cell Lung Cancer Stage II

Interventions: Drug: Gefitinib
Drug: docetaxel
Drug: cisplatin
Procedure: Surgery

First Posted Date: 2014-12-29

Last Posted Date: 2018-01-23

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 1

Registration Number: NCT02326285

Locations: 🇩🇪
Pius-Hospital, Oldenburg, Germany

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)

Phase 2

Terminated

Conditions: Lung Cancer
Progressive Brain Metastases
Breast Cancer
Recurrent Brain Metastases

Interventions: Drug: Cabazitaxel

First Posted Date: 2014-06-18

Last Posted Date: 2018-01-23

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 8

Registration Number: NCT02166658

Locations: 🇩🇪
Kliniken Nordoberpfalz, AG Klinikum Weiden, Medizinische Kliniken I, Weiden, Bayern, Germany

Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer

Phase 2

Completed

Conditions: Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Esophageal Adenocarcinoma
Gastric Neoplasm
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Esophageal Neoplasms

Interventions: Drug: Chemotherapy by Investigator's choice
Drug: S-1 de-escalation

First Posted Date: 2014-05-01

Last Posted Date: 2021-03-26

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 242

Registration Number: NCT02128243

Locations: 🇩🇪
NCT-Med. Onkologie, Heidelberg, Baden-Württemberg, Germany

Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Ductal Adenocarcinoma of the Pancreas

Interventions: Drug: Gem/nab-Pac
Drug: FOLFIFINOX

First Posted Date: 2014-04-29

Last Posted Date: 2021-12-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 168

Registration Number: NCT02125136

Locations: 🇩🇪
Universitätsklinikum Würzburg/Comprehensive Cancer Center Mainfranken, Würzburg, Bayern, Germany

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Phase 2

Completed

Conditions: Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
Poorly Differentiated Malignant Neuroendocrine Carcinoma
Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3
Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3
Neuroendocrine Carcinoma, Grade 3

Interventions: Drug: Everolimus (Afinitor®)

First Posted Date: 2014-04-15

Last Posted Date: 2020-10-28

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 40

Registration Number: NCT02113800

Locations: 🇩🇪
Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Campus Virchow-Klinikum, Berlin, Germany

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

Phase 2

Completed

Conditions: Ductal Adenocarcinoma of the Pancreas
Resectable Pancreatic Cancer

Interventions: Drug: adjuvant nab-paclitaxel/gemcitabine
Drug: perioperative nab-paclitaxel/gemcitabine

First Posted Date: 2014-01-28

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 127

Registration Number: NCT02047513

Locations: 🇩🇪
University of Ulm, Dept. of Internal Medicine I, Ulm, Germany

Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Maintenance Chemotherapy
Drug: Panitumumab (Within maintenance phase)
Drug: Panitumumab (Within re-induction phase)
Drug: mFOLFOX6 (Within re-induction phase)

First Posted Date: 2013-11-25

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 387

Registration Number: NCT01991873

Locations: 🇩🇪
St.-Antonius-Hospital Eschweiler, Eschweiler, Germany
🇩🇪
Zentrum für Tumorbiologie und Integrative Medizin, Klinikum Wilhelmshaven, Wilhelmshaven, Germany

Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer

Phase 2

Completed

Conditions: Ras-wildtype Colorectal Cancer

Interventions: Drug: Erythromycin
Drug: Doxycycline

First Posted Date: 2012-08-20

Last Posted Date: 2016-04-19

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 88

Registration Number: NCT01668498

Locations: 🇩🇪
Universitätsklinikum Mannheim, III. Medizinische Klinik, Mannheim, Germany

Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer

Phase 3

Terminated

Conditions: Esophageal Squamous Cell Cancer

Interventions: Drug: Cisplatin, 5-FU
Drug: Panitumumab

First Posted Date: 2012-06-25

Last Posted Date: 2018-03-02

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 300

Registration Number: NCT01627379

Locations: 🇩🇪
Johannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik, Mainz, Rheinland-Pfalz, Germany

A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer

Conditions: the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine

First Posted Date: 2012-06-25

Last Posted Date: 2013-10-22

Lead Sponsor: AIO-Studien-gGmbH

Registration Number: NCT01626781

Locations: 🇩🇪
Universitätsmedizin Mannheim, III. Medizinische Klinik, Mannheim, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy